|
|
 |
|
| Technology |
|
 |
|
| Treatment of Acid-Related Disorders |
|
Proton Pump Inhibitors (PPIs) are the most efficacious drugs for treatment of acid-related disorders, such as Gastro Esophageal Reflux Disease (GERD), Peptic Ulcer Disease, Dyspepsia, ulceration caused by intake of non-steroidal anti-inflammatory drugs and stress-mediated ulceration. They act by creating a specific blockage of gastric proton pumps, which are responsible for secretion of acid in the stomach. Their activity depends on the level of pre-activated proton pump expressing cells. This pre-activation occurs only when a meal is taken; therefore, it possesses significant limitation of PPI use and activity, i.e. all PPIs must be given in conjunction with meal administration. This requirement limits the patient’s compliance and often restricts on-demand and chronic use of the drug. GERD patients, for example, suffer from frequent nocturnal heartburn and are forbidden from food intake at least three hours prior to sleeping time. Therefore, it is impossible to administer the PPI for the relief of nocturnal symptoms in such patients.
To overcome the meal-dependence of PPIs, VECTA offers the use of meal-mimicking agents. These molecules are capable of activating parietal cells, the targets of PPIs activity that maximize the effect of PPI in a meal-independent manner (Exhibit I.).
Exhibit I.
|
